Literature DB >> 12719580

Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.

Michael B Zwick1, Paul W H I Parren, Erica O Saphire, Sarah Church, Meng Wang, Jamie K Scott, Philip E Dawson, Ian A Wilson, Dennis R Burton.   

Abstract

IgG1 b12 is a broadly neutralizing antibody against human immunodeficiency virus type 1 (HIV-1). The epitope recognized by b12 overlaps the CD4 receptor-binding site (CD4bs) on gp120 and has been a target for vaccine design. Determination of the three-dimensional structure of immunoglobulin G1 (IgG1) b12 allowed modeling of the b12-gp120 interaction in which the protruding third complementarity-determining region (CDR) of the heavy chain (H3) was crucial for antibody binding. In the present study, extensive mutational analysis of the antigen-binding site of Fab b12 was carried out to investigate the validity of the model and to identify residues important for gp120 recognition and, by inference, key to the anti-HIV-1 activity of IgG1 b12. In all, 50 mutations were tested: 40 in H3, 4 each in H2 and L1, and 2 in L3. The results suggest that the interaction of gp120 with H3 of b12 is crucially dependent not only on a Trp residue at the apex of the H3 loop but also on a number of residues at the base of the loop. The arrangement of these residues, including aromatic side chains and side chains that hydrogen bond across the base of the loop, may rigidify H3 for penetration of the recessed CD4-binding cavity. The results further emphasize the importance to gp120 binding of a Tyr residue at the apex of the H2 loop that forms a second finger-like structure and a number of Arg residues in L1 that form a positively charged, shelf-like structure. In general, the data are consistent with the b12-gp120 interaction model previously proposed. At the gene level, somatic mutation is seen to be crucial for the generation of many of the structural features described. The Fab b12 mutants were also tested against the b12 epitope-mimic peptide B2.1, and the reactivity profile had many similarities but also significant differences from that observed for gp120. The paratope map of b12 may facilitate the design of molecules that are able to elicit b12-like activities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719580      PMCID: PMC154005          DOI: 10.1128/jvi.77.10.5863-5876.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  91 in total

1.  A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity.

Authors:  S A Tilley; W J Honnen; M E Racho; M Hilgartner; A Pinter
Journal:  Res Virol       Date:  1991 Jul-Aug

2.  Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.

Authors:  Ralph Pantophlet; Erica Ollmann Saphire; Pascal Poignard; Paul W H I Parren; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein.

Authors:  E Helseth; U Olshevsky; C Furman; J Sodroski
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

4.  A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.

Authors:  D R Burton; C F Barbas; M A Persson; S Koenig; R M Chanock; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

5.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.

Authors:  M Thali; U Olshevsky; C Furman; D Gabuzda; M Posner; J Sodroski
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

6.  Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.

Authors:  D D Ho; J A McKeating; X L Li; T Moudgil; E S Daar; N C Sun; J E Robinson
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

7.  The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.

Authors:  Emmanuel G Cormier; Tatjana Dragic
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Authors:  M Thali; C Furman; D D Ho; J Robinson; S Tilley; A Pinter; J Sodroski
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

Review 9.  Assembly of IgH CDR3: mechanism, regulation, and influence on antibody diversity.

Authors:  L VanDyk; K Meek
Journal:  Int Rev Immunol       Date:  1992       Impact factor: 5.311

10.  Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis.

Authors:  Louise McHugh; Stella Hu; B K Lee; Kenneth Santora; Paul E Kennedy; Edward A Berger; Ira Pastan; Dean H Hamer
Journal:  J Biol Chem       Date:  2002-07-15       Impact factor: 5.486

View more
  51 in total

1.  Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides.

Authors:  Marit Kramski; Rob J Center; Adam K Wheatley; Jonathan C Jacobson; Marina R Alexander; Grant Rawlin; Damian F J Purcell
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

Authors:  Fatima K Ahmed; Brenda E Clark; Dennis R Burton; Ralph Pantophlet
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

3.  Complex binding sites made to order.

Authors:  Jamie K Scott; Ralph Pantophlet; Lisa Craig
Journal:  Nat Biotechnol       Date:  2012-02-08       Impact factor: 54.908

4.  Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.

Authors:  Daniela Tudor; Huifeng Yu; Julien Maupetit; Anne-Sophie Drillet; Tahar Bouceba; Isabelle Schwartz-Cornil; Lucia Lopalco; Pierre Tuffery; Morgane Bomsel
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-20       Impact factor: 11.205

5.  Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

Authors:  Ralph Pantophlet; Rowena O Aguilar-Sino; Terri Wrin; Lisa A Cavacini; Dennis R Burton
Journal:  Virology       Date:  2007-04-06       Impact factor: 3.616

6.  Crystal structure of a 3B3 variant--a broadly neutralizing HIV-1 scFv antibody.

Authors:  K Reed Clark; Scott T R Walsh
Journal:  Protein Sci       Date:  2009-12       Impact factor: 6.725

7.  Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer.

Authors:  Dmitry Lyumkis; Jean-Philippe Julien; Natalia de Val; Albert Cupo; Clinton S Potter; Per-Johan Klasse; Dennis R Burton; Rogier W Sanders; John P Moore; Bridget Carragher; Ian A Wilson; Andrew B Ward
Journal:  Science       Date:  2013-10-31       Impact factor: 47.728

Review 8.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

9.  Signature of Antibody Domain Exchange by Native Mass Spectrometry and Collision-Induced Unfolding.

Authors:  Yasunori Watanabe; Snezana Vasiljevic; Joel D Allen; Gemma E Seabright; Helen M E Duyvesteyn; Katie J Doores; Max Crispin; Weston B Struwe
Journal:  Anal Chem       Date:  2018-05-25       Impact factor: 6.986

10.  Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches.

Authors:  Hwai Wen Chang; Gerhard Frey; Haizhen Liu; Charles Xing; Lawrence Steinman; William J Boyle; Jay M Short
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.